News on Pronova BioPharma and Teva Pharmaceuticals patent litigation

Pronova BioPharma ASA (OSE: PRON) today announced that it has agreed with Teva Pharmaceuticals USA, Inc to dismiss the patent litigation in the United States District Court pertaining to two of Pronova’s U.S. Patents. Pronova Biopharma is still involved in a lawsuit with Teva for two patents relating to fish oil capsule prescription drug Lovaza, which is marketed in the US by GlaxoSmithKline and may turn generic in autumn of 2012. Pronova expects ruling on this matter by Q4 2011, after which it will decide whether to address generic ANDA for Lovaza from Endo Pharmaceuticals.